Abstract
Synopsis
Analysis of Harvest Moon's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
- Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
- Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
- Harvest Moon specializes in the development of complex generics and biosimilars. These products are in-licensed from emerging market copy-biologic developers before they are out-licensed to partners in developed markets, with Harvest Moon's receiving royalties. Harvest Moon has 30 biosimilar products in various stages of development.
YOUR KEY QUESTIONS ANSWERED
- See how Harvest Moon relies on corporate relationships for both sourcing products and commercialization
- Evaluate key products in Harvest Moon's pipeline, which is one of the largest monoclonal antibody biosimilar pipelines globally
Table of Contents
ABOUT THIS REPORT
- Chapter structure
- Strategic insight
- Product analysis
- Operating performance
- Company introduction
- Data sourcing
- PharmaVitae Explorer database
EXECUTIVE SUMMARY
- Harvest Moon biosimilars SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
STRATEGIC INSIGHT
- Harvest Moon plans to use simple biologic products to gain market experience
- Harvest Moon operates a virtual biotech model
- Low-cost products can be sourced from China and Taiwan
- Sales agreements facilitate market entry
- Phase I trials offered as optional add-on
- Products can be launched in emerging markets while waiting for mature market access
KEY PRODUCTS
- Overview
- Harvest Moon biosimilar portfolio
- Human insulin
- Overview
- Human insulin market size
- Key competitors
- Insulin glargine and lispro
- Overview
- Insulin glargine and lispro market size
- Key competitors
- Erythropoietin
- Overview
- Erythropoietin market size
- Key competitors
- Filgrastim and pegfilgrastim
- Overview
- Filgrastim and pegfilgrastim market size
- Key competitors
- Etanercept
- Overview
- Etanercept market size
- Key competitors
- Imiglucerase
- Overview
- Imiglucerase market size
- Key competitors
- Interferon beta-1a and -1b
- Overview
- Interferon beta market size
- Key competitors
- Other products
CORPORATE STRUCTURE
- Background
- Deals and alliances
- Recent developments
APPENDIX
- References
- Exchange rates
TABLES
- Table: Harvest Moon - biosimilar portfolio
- Table: Forecasted human insulin sales in the seven major markets ($m), 2011-16
- Table: Biosimilar human insulin, products currently launched or in development
- Table: Forecasted lispro and glargine insulin sales ($m), 2011-16
- Table: Biosimilar human insulin, insulin glargine, and insulin lispro products currently launched or in development
- Table: Forecasted epoetin and darbepoetin sales ($m), 2011-16
- Table: Harvest Moon - pipeline and marketed biosimilar epoetin drugs
- Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011-16
- Table: Harvest Moon - pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs
- Table: Forecasted Enbrel sales ($m), 2011-16
- Table: Biosimilar etanercept drugs, 2012
- Table: Forecasted interferon beta sales ($m), 2011-16
- Table: Biosimilar imiglucerase products currently launched or in development
- Table: Forecasted interferon beta sales ($m), 2011-16
- Table: Harvest Moon - pipeline and marketed biosimilar interferon beta drugs
- Table: Harvest Moon's other products/candidates in unknown stages of development
- Table: Exchange rates, 2011
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: Harvest Moon SWOT analysis
- Figure: Harvest Moon's partnership and licensee strategy
